Journal of Ovarian Research · Nov 18, 2026

Beyond CA125: evidence-based ranking and stratified use of diagnostic biomarkers for ovarian cancer

By Xian X, Yan M, Lu J et al.

Background Diagnostic biomarkers serve as important adjuncts for the early diagnosis of ovarian cancer. However, single indicators lack sufficient sensitivity and specificity to meet clinical demands. This study systematically synthesized evidence from existing meta-analyses and systematic reviews, compared the diagnostic accuracy of multiple single and combined biomarkers, and explored subgroup factors influencing diagnostic performance. Methods PubMed, Embase, Cochrane Library, and Web of Science were searched to retrieve systematic reviews and meta-analyses on diagnostic biomarkers for ovarian cancer. Methodological quality and certainty of evidence were assessed using A Measurement Tool to Assess Systematic Reviews, version 2 (AMSTAR-2) and Grading of Recommendations Assessment, Development and Evaluation (GRADE), respectively, and pairwise indirect comparisons alongside multi-dimensional subgroup analyses were performed to comprehensively evaluate the biomarkers. Results A total of 67 systematic reviews/meta-analyses were included and synthesized by intended clinical use. For the differential diagnosis of adnexal masses, descriptive indirect comparisons ranked LPA highest for numerical sensitivity (0.92, 95% CI 0.88–0.96) and diagnostic odds ratio, HE4 highest for numerical specificity (0.89, 95% CI 0.88–0.91), and ROMA most balanced (sensitivity 0.86, specificity 0.82), with moderate-certainty evidence supporting HE4 and ROMA. For early detection and screening, no single blood biomarker reached the sensitivity required for standalone screening; multi-marker panels, cfDNA methylation, and AI-based models showed the highest numerical accuracy, with AI-based models reaching a pooled AUC of 0.95 (95% CI 0.92–0.96). For recurrence monitoring, CA125 showed high specificity but moderate sensitivity, and evidence for other markers was limited. Subgroup analyses further showed that diagnostic performance was not fixed but varied with clinical context: accuracy was consistently higher in advanced-stage than early-stage disease and in epithelial than mixed-histology tumours, with the stage- and menopausal-status-related differences reaching significance for ROMA and CA125 but not for HE4, LPA, or OPN; performance of HE4 and CA125 also declined when benign gynaecological disease rather than healthy women served as the control group. These subgroup findings were exploratory and hypothesis-generating. Conclusions The choice of biomarker should be driven by the clinical question rather than by a single global ranking. HE4 and ROMA currently offer the most reliable evidence for preoperative triage of adnexal masses, whereas LPA and AI-based multi-marker models remain promising but unvalidated. For screening and recurrence monitoring, available markers are inadequate as standalone tests, and future research should prioritize prospective, externally validated multi-marker strategies with prespecified subgroup hypotheses. These conclusions are descriptive and hypothesis-generating, and they should not be extended beyond the corresponding clinical scenario.

doi.org/10.1186/s13048-026-02307-3Open accessBiomarkers

AgingResearch.News